Diversity of Cortical and Subcortical MS Pathology/Lesions Revealed by 7T MRI

A. N. Dula1,2, S. Pawate1, E. B. Welch1,4, R. G. Avison1, S. Sriram1, J. L. Creasy2, J. C. Gore1,2, and M. J. Avison1,2

1Institute of Imaging Science, Vanderbilt University, Nashville, TN, United States, 2Radiology and Radiological Sciences, Vanderbilt Medical Center, Nashville, TN, United States, 3Neurology and Immunology, Vanderbilt Medical Center, Nashville, TN, United States, 4MR Clinical Science, Philips Healthcare, Cleveland, OH, United States

Purpose
MRI is well established as the imaging modality of choice for the diagnosis of MS and its response to therapy. The improvements in sensitivity and spatial resolution that have accrued with increasing field strengths, up to the current clinical standard of 3T, have provided corresponding improvements in the conspicuity of MS lesions [2-4], and with the recent introduction of 7T human clinical scanners, there is reason to expect further improvement in sensitivity, as well as novel information regarding MS pathology in vivo [5, 6]. While the classical view of MS is one of inflammatory demyelinating lesions in white matter, cortical grey matter (GM) atrophy and focal cortical lesions are also hallmarks of the disease [7, 8]. Cortical lesions show evidence of non-inflammatory demyelination [9, 10], and there is evidence that GM pathology may contribute significantly to the clinical disability in patients [11]. Similarly, there is strong neuropathological evidence that WM lesions originate from perivascular inflammatory foci [6], suggesting that these small lesions may represent early biomarkers of relapse and/or response to therapy. Both GM and small perivascular WM lesions are poorly visualized by standard MRI protocols at 1.5 or 3T. The goal of the present study was to assess the potential for 7T neuroimaging of MS, with particular emphasis on improving conspicuity of MS pathology not previously observed by MRI at lower fields.

Methods
Using a protocol approved by the Vanderbilt University Medical Center IRB, patients with progressive MS were scanned on a Philips Achieva 7T scanner (Philips Healthcare, Cleveland, OH) equipped with a 16-channel NOVA head coil. The 7T MS protocol included: FLAIR (TR/TI/TE = 15000/2800/44ms; 0.6x0.6x2.5mm voxel; imaging time = 6:30 min); T1W 3D fast field echo (FFE, TR/TE = 9.1/4.5 ms; FA = 10°; 0.72x0.72x1.75 mm voxel; imaging time = 9 min); Multi-echo gradient echo (TR/TE/deltaTE = 22/12/2ms FA = 10°; 0.72x0.72x0.9 mm voxel; imaging time = 4:04 min); Pre- and post-contrast T1W spin echo (TR/TE = 4.3/2.24ms 0.5x0.5x3mm voxel; imaging time = 3:47 min). For the contrast-enhanced exams, images were collected following ½ (0.05 mg/kg) and full (0.1 mg/kg) dose Gd-DTPA (Magnevist®, Schering, Berlin, Germany). Signal intensities (SI) of regions of interest (ROIs) were measured on normalized T1W images. Contrast to noise ratios (CNR) were examined for varying doses of Gd-DTPA.

Results
Cortical GM pathology was evident as focal hypointensities on high-resolution 3D-FFE images (Fig 1). These lesions were not evident on FLAIR, nor on T1W SE pre- and post-contrast, consistent with previous studies at lower fields. High resolution T2*W and susceptibility weighted (SW) images revealed perivascular lesions that appear to form cuffs around deep medullary veins (Fig 2). Finally, full dose contrast yielded ~2-fold greater enhancement in lesions than did ½ dose (Fig 3), suggesting that with the increased SNR available at 7T, lower contrast doses may provide lesion detectability comparable to standard dose at 1.5 or 3T.

Conclusions
The course of MS is highly variable and better markers of disease activity and response to therapy are needed. In addition to the pathology revealed by MRI at 1.5 and 3T, ultra-high field MRI also reveals cortical and perivascular MS lesions that reflect different aspects of MS neuropathology.

References